Post-stroke pharmacological intervention: Promoting brain recovery from injury in the future

Neuropharmacology

Volumn 59, Issue 7-8, 2010, Pages 650-653

  Barone, Frank C ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; NEU DIFFERENTIATION FACTOR; NEURITE PROMOTING FACTOR 2; NEUROTROPHIC FACTOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE;

BRAIN INJURY; BRAIN ISCHEMIA; CLINICAL TRIAL; CONVALESCENCE; DRUG EFFECT; DRUG SAFETY; FIBRINOLYTIC THERAPY; HUMAN; INDUCED HYPOTHERMIA; NONHUMAN; NOTE; PRIMARY PREVENTION; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; STROKE;

ANIMALS; HUMANS; ISCHEMIC ATTACK, TRANSIENT; NEUREGULIN-1; NEUROPROTECTIVE AGENTS; RATS; STROKE; TIME FACTORS;

EID: 77958104367     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.08.016     Document Type: Note

References (60)

1. Alvarez-Buylla A., Lois C. Neuronal stem cells in the brain of adult vertebrates. Stem Cells 1995, 13:263-272.
2. Bhang S.H., Lee Y.E., Cho S.W., Shim J.W., Lee S.H., Choi C.Y., Chang J.W., Kim B.S. Basic fibroblast growth factor promotes bone marrow stromal cell transplantation-mediated neural regeneration in traumatic brain injury. Biochem. Biophys. Res. Commun. 2007, 359:40-45.
3. Barone F.C. Ischemic stroke intervention requires mixed cellular protection of the penumbra. Curr. Opin. Investig. Drugs 2009, 10:220-223.
4. Barone F.C., Feuerstein G.Z. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J. Cereb. Blood Flow Metab. 1999, 19:819-834.
5. Biernaskie J., Chernenko G., Corbett D. Efficacy of rehabilitative experience declines with time after focal ischemic brain injury. J. Neurosci. 2004, 24:1245-1254.
6. Burns T.C., Verfaillie C.M., Low W.C. Stem cells for ischemic brain injury: a critical review. J. Comp. Neurol. 2009, 515:125-144.
7. Carmichael S.T. Themes and strategies for studying the biology of stroke recovery in the poststroke epoch. Stroke 2008, 39:1380-1388.
8. Chavez J.C., Hurko O., Barone F.C., Feuerstein G.Z. Pharmacologic interventions for stroke: looking beyond the thrombolysis time window into the penumbra with biomarkers, not a stopwatch. Stroke 2009, 40:558-563.
9. Cho G.W., Koh S.H., Kim M.H., Yoo A.R., Noh M.Y., Oh S., Kim S.H. The neuroprotective effect of erythropoietin-transduced human mesenchymal stromal cells in an animal model of ischemic stroke. Brain Res. 2010, (Epub ahead of print).
10. Chopp M., Steinberg G.K., Kondziolka D., Lu M., Bliss T.M., Li Y., Hess D.C., Borlongan C.V. Who's in favor of translational cell therapy for stroke: STEPS forward please?. Cell Transplant. 2009, 18:691-693.
11. Das S., Basu A. Inflammation: a new candidate in modulating adult neurogenesis. J. Neurosci. Res. 2008, 86:1199-1208.
12. Del Zoppo G.J. Relationship of neurovascular elements to neuron injury during ischemia. Cerebrovasc. Dis. 2009, 27(Suppl. 1):65-76.
13. Del Zoppo G.J., Saver J.L., Jauch E.C., Adams H.P. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009, 40:2945-2948. American Heart Association Stroke Council.
14. Di Filippo M., Tozzi A., Costa C., Belcastro V., Tantucci M., Picconi B., Calabresi P. Plasticity and repair in the post-ischemic brain. Neuropharmacology 2008, 55:353-362.
15. Dirnagl U. Bench to bedside: the quest for quality in experimental stroke research. J. Cereb. Blood Flow Metab. 2006, 26:1465-1478.
16. Ehrenreich H., Weissenborn K., Prange H., Schneider D., Weimar C., Wartenberg K., Schellinger P.D., Bohn M., Becker H., Wegrzyn M., Jähnig P., Herrmann M., Knauth M., Bähr M., Heide W., Wagner A., Schwab S., Reichmann H., Schwendemann G., Dengler R., Kastrup A., Bartels C. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009, 40:647-656. EPO Stroke Trial Group.
17. Ekdahl C.T., Kokaia Z., Lindvall O. Brain inflammation and adult neurogenesis: the dual role of microglia. Neuroscience 2009, 158:1021-1029.
18. Elijovich L., Chong J.Y. Current and future use of intravenous thrombolysis for acute ischemic stroke. Curr. Atheroscler. Rep. 2010, 12:316-321.
19. Erlandsson A., Lin A., Yu F., Morshead C.M. Immunosuppression promotes endogenous neural stem and progenitor cell migration and tissue regeneration after ischemic injury. Exp. Neurol. 2010, (Epub ahead of print; Proof available on-line).
20. Feuerstein G.Z., Zaleska M.M., Krams M., Wang X., Day M., Rutkowski J.L., Finklestein S.P., Pangalos M.N., Poole M., Stiles G.L., Ruffolo R.R., Walsh F.L. Missing steps in the STAIR case: a translational medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J. Cereb. Blood Flow Metab. 2008, 28:217-219.
21. Finklestein S.P., Caday C.G., Kano M., Berlove D.J., Hsu C.Y., Moskowitz M., Klagsbrun M. Growth factor expression after stroke. Stroke 1990, 21(Suppl. 11):III122-III124.
22. Fisher M., Feuerstein G., Howells D.W., Hurn P.D., Kent T.A., Savitz S.I., Lo E.H. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009, 40:2244-2250. STAIR Group.
23. Fisher M., Hanley D.F., Howard G., Jauch E.C., Warach S. Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes. Stroke 2007, 38:245-248. STAIR Group.
24. Ginsberg M.D. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 2008, 55:363-389.
25. Goldman S.A. Disease targets and strategies for the therapeutic modulation of endogenous neural stem and progenitor cells. Clin. Pharmacol. Ther. 2007, 82:453-460.
26. Greenberg D.A., Jin K. Growth factors and stroke. NeuroRx 2006, 3:458-465.
27. Gutiérrez M., Merino J.J., de Leciñana M.A., Díez-Tejedor E. Cerebral protection, brain repair, plasticity and cell therapy in ischemic stroke. Cerebrovasc. Dis. 2009, 27(Suppl. 1):177-186.
28. Jerndal M., Forsberg K., Sena E.S., Macleod M.R., O'Collins V.E., Linden T., Nilsson M., Howells D.W. A systematic review and meta-analysis of erythropoietin in experimental stroke. J. Cereb. Blood Flow Metab. 2010, 30:961-968.
29. Jia L., Chopp M., Zhang L., Lu M., Zhang Z. Erythropoietin in combination of tissue plasminogen activator exacerbates brain hemorrhage when treatment is initiated 6 hours after stroke. Stroke 2010, (Epub ahead of print).
30. Johansson B.B. Brain plasticity and stroke rehabilitation. The Willis lecture. Stroke 2000, 31:223-230.
31. Kazanis I. The subependymal zone neurogenic niche: a beating heart in the centre of the brain: how plastic is adult neurogenesis? Opportunities for therapy and questions to be addressed. Brain 2009, 132(Pt 11):2909-2921.
32. Kawamata T., Speliotes E.K., Finklestein S.P. The role of polypeptide growth factors in recovery from stroke. Adv. Neurol. 1997, 73:377-382.
33. Kawamata T., Dietrich W.D., Schallert T., Gotts J.E., Cocke R.R., Benowitz L.I., Finklestein S.P. Intracisternal basic fibroblast growth factor enhances functional recovery and up-regulates the expression of a molecular marker of neuronal sprouting following focal cerebral infarction. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:8179-8184.
34. Kim K.N., Oh S.H., Lee K.H., Yoon D.H. Effect of human mesenchymal stem cell transplantation combined with growth factor infusion in the repair of injured spinal cord. Acta Neurochir. 2006, (Suppl. 99):133-136.
35. Legos J.J., Barone F.C. Update on pharmacological strategies for stroke: prevention, acute intervention and regeneration. Curr. Opin. Investig. Drugs 2003, 4:847-858.
36. Leker R.R., Lasri V., Chernoguz D. Growth factors improve neurogenesis and outcome after focal cerebral ischemia. J. Neural Transm. 2009, 116:1397-1402.
37. Li Y., Xu Z., Ford G.D., Croslan D.R., Cairobe T., Li Z., Ford B.D. Neuroprotection by neuregulin-1 in a rat model of permanent focal cerebral ischemia. Brain Res. 2007, 1184:277-283.
38. Lichtenwalner R.J., Parent J.M. Adult neurogenesis and the ischemic forebrain. J. Cereb. Blood Flow Metab. 2006, 26:1-20.
39. Liu Z., Li Y., Zhang Z.G., Cui X., Cui Y., Lu M., Savant-Bhonsale S., Chopp M. Bone marrow stromal cells enhance inter- and intracortical axonal connections after ischemic stroke in adult rats. J. Cereb. Blood Flow Metab. 2010, 30:1288-1295.
40. Liu Z., Li Y., Qu R., Shen L., Gao Q., Zhang X., Lu M., Savant-Bhonsale S., Borneman J., Chopp M. Axonal sprouting into the denervated spinal cord and synaptic and postsynaptic protein expression in the spinal cord after transplantation of bone marrow stromal cell in stroke rats. Brain Res. 2007, 1149:172-180.
41. Lo E.H., Dalkara T., Moskowitz M.A. Mechanisms, challenges and opportunities in stroke. Nat. Rev. Neurosci. 2003, 4:399-415.
42. Lo E.H. A new penumbra: transitioning from injury into repair after stroke. Nat. Med. 2008, 14:497-500.
43. Lois C., García-Verdugo J.M., Alvarez-Buylla A. Chain migration of neuronal precursors. Science 1996, 271:978-981.
44. Mahmood A., Lu D., Chopp M. Intravenous administration of marrow stromal cells (MSCs) increases the expression of growth factors in rat brain after traumatic brain injury. J. Neurotrauma 2004, 21:33-39.
45. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 1995, 333:1581-1587.
46. Nedergaard M., Dirnagl U. Role of glial cells in cerebral ischemia. Glia 2005, 50:281-286.
47. Ohab J.J., Fleming S., Blesch A., Carmichael S.T. A neurovascular niche for neurogenesis after stroke. J. Neurosci. 2006, 26:13007-13016.
48. Peru R.L., Mandrycky N., Nait-Oumesmar B., Lu Q.R. Paving the axonal highway: from stem cells to myelin repair. Stem Cell Rev. 2008, 4:304-318.
49. Savitz S.I. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp. Neurol. 2007, 205:20-25.
50. Savitz S.I., Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann. Neurol. 2007, 61:396-402.
51. Savitz S.I., Dinsmore J.H., Wechsler L.R., Rosenbaum D.M., Caplan L.R. Cell therapy for stroke. NeuroRx 2004, 1:406-414.
52. Shen L.H., Li Y., Chen J., Zacharek A., Gao Q., Kapke A., Lu M., Raginski K., Vanguri P., Smith A., Chopp M. Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke. J. Cereb. Blood Flow Metab. 2007, 27:6-13.
53. STAIR Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999, 30:2752-2758.
54. Wakabayashi K., Nagai A., Sheikh A.M., Shiota Y., Narantuya D., Watanabe T., Masuda J., Kobayashi S., Kim S.U., Yamaguchi S. Transplantation of human mesenchymal stem cells promotes functional improvement and increased expression of neurotrophic factors in a rat focal cerebral ischemia model. J. Neurosci. Res. 2010, 88:1017-1025.
55. Xiong Y., Mahmood A., Chopp M. Angiogenesis, neurogenesis and brain recovery of function following injury. Curr. Opin. Investig. Drugs 2010, 11:298-308.
56. Xu J., Liu X., Chen J., Zacharek A., Cui X., Savant-Bhonsale S., Chopp M., Liu Z. Cell-cell interaction promotes rat marrow stromal cell differentiation into endothelial cell via activation of TACE/TNF-alpha signaling. Cell Transplant. 2010, 19:43-53.
57. Xu Z., Croslan D.R., Harris A.E., Ford G.D., Ford B.D. Extended therapeutic window and functional recovery after intraarterial administration of neuregulin-1 after focal ischemic stroke. J. Cereb. Blood Flow Metab. 2006, 26:527-535.
58. Xu Z., Ford G.D., Croslan D.R., Jiang J., Gates A., Allen R., Ford B.D. Neuroprotection by neuregulin-1 following focal stroke is associated with the attenuation of ischemia-induced pro-inflammatory and stress gene expression. Neurobiol. Dis. 2005, 19:461-470.
59. Zhang Z.G., Chopp M. Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic. Lancet Neurol. 2009, 8:491-500.
60. Zhang R.L., Zhang Z.G., Chopp M. Ischemic stroke and neurogenesis in the subventricular zone. Neuropharmacology 2008, 55:345-352.